QIAGEN has expanded its collaboration with AstraZeneca to create companion diagnostics for AstraZeneca's forthcoming chronic disease treatments.
According to the partnership, QIAGEN will create and validate a genotyping assay using its QIAstat-Dx testing platform. It uses single-use cartridges with built-in sample processing, onboard reagents, and multiplex real-time PCR to detect and differentiate between multiple biomarkers, claiming to provide results within an hour.
This will enable medical professionals to carry out genotyping when patients undergo regular clinical examinations and make decisions concerning patient suitability for AstraZeneca's genome-targeted medicines.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.